Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice try, same sentence, read on…..5 calendar days
Well, nobody knows what their plans are. Until now it's just a bunch of lies, just look at the press releases. Only a merger with Velocity can turn this around. No indication they're willing to throw in another company with revenue
Yep, totally insane. But what puzzles me most is that the majority of all mutations in the balance/revenue sheet are intercompany mutations. They could have those general ledger changes the day after the Q ends.
I'm thinking about 2 possibilities:
1) they do this on purpose, punishing shareholders for being so stupid to own shares in this shithole
2) they're really trying but are to fokking stupid to understand how to do it better.
I'm inclined to think it's the latter option.
no words for this management, incompetence beyond belief
No, 5 calendar days, read the NT-10Q. But yesterday the exchanges were closed (president’s day), so they need to file today before midnight
Markets closed today, MVNT fins due today
You mean you hope revenue > 378K , or it would be the third consecutive quarter that revenue is down
Hilarious!
After getting Pink Current OTC and sharing the news about a new large client in Montana, it has been very quiet. Probably because they could not build their brand INNOVAQOR as long as FINRA didn't approve the ticker change. Well that's done now. I expect some very good news shortly
Looks like everything's according to plan, but it took a long time for FINRA to approve the new symbol. Think we've seen the bottom here. Waiting for news about new clients, will blow the SP above a dime
$VMCS 0.0073 OS 245 M MC 1.5 M
Ticker change TOMORROW to INQR (Innovaqor Inc.)
Volume is back, INQR has a great future:
- $20M invested,
- has revenue,
- signed large med. chain (3 locations) in September 2022,
- AUDITED financials,
- fully SEC reporting, when above .01 up-list to OTCQB,
- extremely undervalued, target short-term: .05-.10
https://www.otcmarkets.com/stock/VMCS/news/InnovaQor-Incconfirms-trading-symbol-change-to-INQR?id=389682
$VMCS 0.0073 OS 245 M MC 1.5 M
Ticker change TOMORROW to INQR Innovaqor Inc.
Volume is back, INQR has a great future:
- $20M invested,
- has revenue,
- signed large med. chain (3 locations) in September 2022,
- AUDITED financials,
- fully SEC reporting, when above .01 up-list to OTCQB,
- extremely undervalued, target short-term: .05-.10
https://www.otcmarkets.com/stock/VMCS/news/InnovaQor-Incconfirms-trading-symbol-change-to-INQR?id=389682
Interesting week ahead. They have to file the quarterly 15/02 or file a Notification for late filing to get a 5 day extension. Let's see. Then we probably get a Tweet that the fins are posted on OTC and Updates to follow, STAY TUNED. Fokkers!
It needs more than that, either blow-out financials (due next week) or an official PR about a merger with Velocity or another company. It's true that volume is picking up, but nothing spectaculair. And the jump from 0.0095 to 0.0128 was on a minimal trade of 100 shares, 2 hours before close. Bummer
$HALB 0.0125 OS 516 million
Watch this! They developed a treatment to fully eradicate antibiotic resistant bacteria from blood and CSF.
Strains of bacteria received from the CDC.
Halberd Demonstrates Eradication of CDC Provided Antibiotic Resistant Bacteria
Press Release | 02/08/2023
JACKSON CENTER, PA / ACCESSWIRE / February 8, 2023 / Halberd Corporation (OTC PINK:HALB) has demonstrated its patent-pending extracorporeal laser eradication process is capable of eliminating antibiotic resistant strains of CDC provided bacteria samples. Previously, Halberd demonstrated success in eliminating Escherichia coli and other Gram-Negative bacteria at Youngstown State University (YSU). The research is being carried out by Dr. Chester Cooper and Dr. W. Gregg Sturrus with the assistance of student scholar lab assistants
Link:
https://www.otcmarkets.com/stock/HALB/news/Halberd-Demonstrates-Eradication-of-CDC-Provided-Antibiotic-Resistant-Bacteria?id=389171
$HALB 0.0125 OS 516 million
Watch this! They developed a treatment to fully eradicate antibiotic resistant bacteria from blood and CSF.
Strains of bacteria received from the CDC.
Halberd Demonstrates Eradication of CDC Provided Antibiotic Resistant Bacteria
Press Release | 02/08/2023
JACKSON CENTER, PA / ACCESSWIRE / February 8, 2023 / Halberd Corporation (OTC PINK:HALB) has demonstrated its patent-pending extracorporeal laser eradication process is capable of eliminating antibiotic resistant strains of CDC provided bacteria samples. Previously, Halberd demonstrated success in eliminating Escherichia coli and other Gram-Negative bacteria at Youngstown State University (YSU). The research is being carried out by Dr. Chester Cooper and Dr. W. Gregg Sturrus with the assistance of student scholar lab assistants
Link:
https://www.otcmarkets.com/stock/HALB/news/Halberd-Demonstrates-Eradication-of-CDC-Provided-Antibiotic-Resistant-Bacteria?id=389171
4 months later, still no press release, but Thank you shareholders and stay tuned!
$HALB $0.008 OS 516 Million
Starts animal testing at Mississippi State of their patent-pending nasal spay to block BRAIN TRAUMA (think NFL!!!)
JACKSON CENTER, PA / ACCESSWIRE / January 31, 2023 / Halberd Corporation (OTC PINK:HALB) confirmed that animal testing at Mississippi State University (MSU) will focus on Halberd's patent-pending nasal spray to mitigate the effects of Traumatic Brain Injury (TBI), when administered shortly after sustaining a head Injury. The work will be conducted over the next several months under the direction of Dr. Russell Carr, of the College of Veterinary Medicine.
Following Halberd's in vitro successful eradication of each known antigen associated with head trauma, including TBI, in collaboration with Youngstown State University, in vivo studies are to commence at Mississippi State University. Funding for the program has already been approved.
Head trauma initiates a cascade of overproduction of certain proteins and inflammatory cytokines in the brain. This overproduction, depending on the magnitude of the injury, often manifests itself in neurological changes in behavior, such as PTSD, aggression and suicide ideation. Halberd's triple-action nasal spray is designed to counteract these TBI-related complications by blocking the overproduction mechanism and allowing the brain to recover naturally. The benefits of such an approach in treating head injuries to military personnel, contact sports athletes and ordinary people who experience head trauma are monumental.
Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board-certified attending neurologist stated, "We have been very impressed by the protocol for testing traumatic brain injury in animals by the professors at Mississippi State University. What sets Halberd's nasal spray treatment apart is the ability to administer the treatment soon after injury in any setting, thus reducing the potential for serious permanent neurological damage."
William A. Hartman, Chairman, President & CEO of Halberd Corporation, added, "Selecting a source for animal testing of our anti-traumatic brain injury nasal spray was a very difficult process. Many universities we met with simply didn't have the process, experience, or expertise to conduct the tests in a manner that would yield our desired results. Mississippi State University has developed the procedures and delivered a test protocol that meets Halberd's rigid specifications. We look forward to a successful program with Mississippi State University."
$HALB $0.008 OS 516 Million
Starts animal testing at Mississippi State of their patent-pending nasal spay to block BRAIN TRAUMA (think NFL!!!)
JACKSON CENTER, PA / ACCESSWIRE / January 31, 2023 / Halberd Corporation (OTC PINK:HALB) confirmed that animal testing at Mississippi State University (MSU) will focus on Halberd's patent-pending nasal spray to mitigate the effects of Traumatic Brain Injury (TBI), when administered shortly after sustaining a head Injury. The work will be conducted over the next several months under the direction of Dr. Russell Carr, of the College of Veterinary Medicine.
Following Halberd's in vitro successful eradication of each known antigen associated with head trauma, including TBI, in collaboration with Youngstown State University, in vivo studies are to commence at Mississippi State University. Funding for the program has already been approved.
Head trauma initiates a cascade of overproduction of certain proteins and inflammatory cytokines in the brain. This overproduction, depending on the magnitude of the injury, often manifests itself in neurological changes in behavior, such as PTSD, aggression and suicide ideation. Halberd's triple-action nasal spray is designed to counteract these TBI-related complications by blocking the overproduction mechanism and allowing the brain to recover naturally. The benefits of such an approach in treating head injuries to military personnel, contact sports athletes and ordinary people who experience head trauma are monumental.
Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board-certified attending neurologist stated, "We have been very impressed by the protocol for testing traumatic brain injury in animals by the professors at Mississippi State University. What sets Halberd's nasal spray treatment apart is the ability to administer the treatment soon after injury in any setting, thus reducing the potential for serious permanent neurological damage."
William A. Hartman, Chairman, President & CEO of Halberd Corporation, added, "Selecting a source for animal testing of our anti-traumatic brain injury nasal spray was a very difficult process. Many universities we met with simply didn't have the process, experience, or expertise to conduct the tests in a manner that would yield our desired results. Mississippi State University has developed the procedures and delivered a test protocol that meets Halberd's rigid specifications. We look forward to a successful program with Mississippi State University."
I don't think they will merge. Last 2 quarters revenue was down and that probably means that Velocity's turnover (biggest client/supplier) was down as well. But you could be right about Elvis.....
Turnover development MVNT from the start:
Q 30/06/2021 0 K
Q 30/09/2021 206 K
Q 31/12/2021 378 K
Q 31/03/2022 348 K
Q 30/06/2022 113 K
Q 30/09/2022 128 K
Due in 2 weeks Q 31/12/2022, higher or lower than 378 K ???
stay tuned hahahah
don't think so, because next quarterly will probably be filed late as well
Some say everything here's okay because there's been no dilution and F&F invested a million of their own cash. Very true. But did it ever cross your mind that F&F are screwed as well, because without a major merger or exploding revenue there's no option left for them to get their million back.
I think you know better. This is just like when Dab was running the joint and you bought your VSHC shares for nothing. These guys need 3 months (see tweet 10/06/2022) to produce a press release, probably because there's nothing to tell.
Movement Industries
@mvmntin
·
Oct 6, 2022
Attorney letter has been posted to bring $MVNT back to current. We would like to highlight that our financial show 480% revenue growth year over year. Official press release very soon. Thank you shareholders.
Movement Industries
@mvmntin
·
Jan 5
Our 09/30/2022 Quarterly Report is posted on OTC Markets. We expect to be Pink Current soon. Updates to follow. Stay tuned. $MVNT
hahahahah (Pink Shit)
really, you can’t be serious, you’re the only one left believing these guys
(On Twitter 2 believers left but I think both accounts are yours?)
Movement Industries
@mvmntin
·
19h
Our 09/30/2022 Quarterly Report is posted on OTC Markets. We expect to be Pink Current soon. Updates to follow. Stay tuned. $MVNT
UPDATES TO FOLLOW. But WHEN? And What news? Velocity or more bull?
In the last reported 2 quarters revenue fell back to 241K (128 + 113) with a net loss of 123K! That's hilarious given their statement they want to grow organically to 100 million.
their latest press release (03/09/2022) goes back 10 months!!!
Hope you're right, they HAD a plan but until know execution sucks. If no mention of merging in Velocity and other companies I will start selling
yeah, that's all we can hope for
will be a hell of a job for MVNT to produce a credible 2022 recap and outlook
nobody knows (but the disappointing trend in revenue tells me there's hardly any synergy between MVNT and Velocity and probably Velocity's revenue is in decline as well)
Really?
Financials per 09/30/2022 filed. Revenue a lousy 128K and a 55K loss. Revenue is down 78K from the same period last year. Seems they peaked in Q1 2022 (348K). Revenue this Q and the Q before really very very disappointing. No subsequent events. Total loss
Just a reminder of what a jerk Jack Leal is (from PR 03/09/2022):
"Mr. Leal, new Chief Financial Officer, affirmed, “I personally believe in our Company’s products, services and our CEO, Mr. Nguyen. My goal is to ensure that the Company and stakeholders are receiving TIMELY and accurate financial information, which ensures the Company can move toward even greater growth opportunities."
"Timely and accurate financial information" ........hilarious
Nope, they filed the attorney letter after filing the annual report on 10/06/2022. No need to file another one.
Why would the fins be under review by legal? Don’t they trust their own auditor? Don’t they trust Jack Leal?